Ascendis Pharma A/S ASND

About Ascendis Pharma A/S (ASND): stock profile, AI score and financials

Ascendis Pharma A/S (ASND) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASND at 49.9/100 on a composite quality score built from its SEC filings, placing it at rank #1,643 of 2,925 stocks — the bottom half of the AI-ranked universe. ASND scores in the top quartile across revenue growth (95.6). Areas of concern include institutional flow (0.8) and balance sheet strength (11.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q4 2025), Ascendis Pharma A/S reports quarterly revenue of $247.5M, net income of $-33.6M, an operating margin of 4.0%. Top institutional holders of ASND by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Avoro Capital Advisors, based on the most recent SEC filings. ASND trades on the Nasdaq exchange and files with the SEC under CIK 1612042. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASND daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ascendis Pharma A/S directly from SEC EDGAR.

Financials through the period ended Dec 31, 2025SEC EDGAR: CIK 1612042 →